Compare Immunovant Inc. Common Stock (IMVT) vs McDonald's Corp (MCD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Immunovant Inc. Common Stock vs McDonald's Corp — how do they compare? Immunovant Inc. Common Stock trades at $30.01 (market cap $6.62B), while McDonald's Corp trades at $236.09 (market cap $163.38B). The key difference: McDonald's Corp is far larger — about 24.7× Immunovant Inc. Common Stock's market cap, and McDonald's Corp pays a 3.34% dividend while Immunovant Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Immunovant Inc. Common Stock for 0 Days and McDonald's Corp for 164 Days on average.
| IMVT | MCD | |
|---|---|---|
Market Cap | $6.62B | $163.38B |
Volume | 1,131,364 | 4,647,229 |
Sector | Health | Consumer Cyclical |
52-Week High | $44.96 | $341.06 |
52-Week Low | $17.03 | $230.88 |
Typical Hold Time | 0 Days | 164 Days |
Enterprise Value | $5.72B | $217.15B |
Dividend Yield | — | 3.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
McDonald's (MCD) trades at $236.9, up 1.91% for the day, with a bearish technical signal despite recent earnings beats. The company reported strong fundamentals with 2025 revenue of $26.89B and net income of $8.56B, supported by a 57.38% gross margin. Recent news highlights a new 'NEXT' growth strategy focusing on automation and menu innovation to counter competitive pressures.
The outlook is mixed: analyst consensus is bullish with a $286.95 price target, but technical indicators and macroeconomic headwinds pose risks. Investment opportunity lies in McDonald's resilient franchise model and dividend yield, though inflation and execution of new initiatives are key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Immunovant Inc. Common Stock
Immunovant is a clinical-stage immunology company developing therapies for autoimmune diseases. Its pipeline includes anti-FcRn antibody candidates designed for subcutaneous administration.
Read more on IMVT →About McDonald's Corp
McDonald's Corporation franchises and operates fast-food restaurants in the global restaurant industry. The Company's restaurants serves a variety of value-priced menu products in countries around the world.
Read more on MCD →
